PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042553
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2042553
Bronchoscopy Market size was valued at US$ 3,190.88 Million in 2025, expanding at a CAGR of 8.14% from 2026 to 2033.
Bronchoscopy is a medicinal method that used to inspect the inside of the lungs and airways with the support of a thin flexible or rigid tube termed as bronchoscope, which transmits a light and camera. It is inserted via nose or mouth and directed into the respiratory passages to help doctors detect lung conditions, collect tissue or fluid samples, remove blockages, or deliver treatment. This procedure is commonly used in hospitals for diagnosing infections, tumors, and other breathing-related issues in a minimally invasive manner. These methods are widely supported by global public health institutions as an important respiratory diagnostic tool. Organizations such as the U.S. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), and National Cancer Institute recognize its role in lung disease evaluation and cancer detection. The World Health Organization (WHO) also focuses on increasing respiratory illnesses and cancer cases as vital health concerns that need advanced diagnostic methods like bronchoscopy.
Bronchoscopy Market- Market Dynamics
Expansion of healthcare infrastructure and diagnostic capability
Advancement in hospital infrastructure and diagnostic availability is supporting adoption of bronchoscopy in both advanced and developing healthcare surroundings. As healthcare systems enhance, there is better approach to advanced medical equipment that lets doctors to study lung and airway conditions more accurately and at a former stage. This makes bronchoscopy more widely available beyond only major hospitals, extending its use into a broader range of clinical settings. Government health bodies emphasize continuous investment in diagnostic capacity to strengthen early disease detection. For example, the Ministry of Health and Family Welfare (India) highlights ongoing expansion of tertiary care hospitals and respiratory care units.
Similarly, the National Health Service (NHS, UK) continues to promote diagnostic pathways for lung disease detection. The China National Health Commission (NHC) also focuses on strengthening hospital-based respiratory diagnostics to manage increasing patient demand. From the industry outlook, Olympus Corporation has expanded its endoscopy portfolio to support broader hospital deployment of bronchoscopy systems, while Pentax Medical (HOYA Group) provides imaging solutions aimed at improving diagnostic workflow efficiency in clinical environments.
The Global Bronchoscopy Market is segmented on the basis of Product Type, Application, Usage, End User, and Region.
The market is alienated into two categories as per product type: flexible bronchoscopy and rigid bronchoscopy. The flexible bronchoscopy is positioned to contribute notably to the market due to its clinical usability, patient comfort, and suitability for routine diagnostic and therapeutic airway measures. It is commonly preferred in hospitals because it allows deeper navigation into smaller airways with less discomfort and does not always require complex operating room settings, making it more adaptable across different care environments. Many industries like, Ambu A/S has reported strong adoption of its single-use flexible bronchoscopy systems across intensive care settings, reflecting growing clinical preference for infection-controlled procedures. In the same way, Boston Scientific Corporation has highlighted increased utilization of its flexible bronchoscopic navigation and intervention tools in pulmonary care programs, supporting wider application in minimally invasive lung diagnostics and treatment workflows.
The market is differed into two classes on the basis of usage: reusable and disposable. The reusable continues to suggest notable contribution in clinical practice due to its occurrence in hospitals, cost efficiency over multiple procedures, and suitability for high-volume diagnostic and therapeutic workflows. Many healthcare facilities prefer reusable systems where strict sterilization protocols are already established, allowing repeated use without frequent replacement, which supports consistent operational planning in respiratory departments. From the business side, Fujifilm Healthcare has expanded its reusable endoscopy platform with enhanced imaging systems designed to improve procedural accuracy and long-term usability in hospital settings. Similarly, Karl Storz SE & Co. KG continues to supply reusable bronchoscopic systems widely adopted in surgical and diagnostic environments, supporting hospitals with durable instruments and advanced visualization technology for repeated clinical applications in airway examination and treatment workflows.
Bronchoscopy Market- Geographical Insights
A systematic understanding of geographical patterns designates that the market displays a strong and structured demand base in North America, as it is supported by advanced healthcare systems, high respiratory disease burden, and well-developed interventional pulmonology services. Government healthcare data supports this steady requirement. The Centers for Disease Control and Prevention reports a continuous presence of chronic respiratory conditions such as COPD, which often require diagnostic bronchoscopy for evaluation and monitoring. The National Institutes of Health supports ongoing research in lung disease detection and minimally invasive respiratory procedures, encouraging wider clinical adoption. In addition, the National Health Service data used in comparative global studies shows increasing reliance on bronchoscopy for early lung disease diagnosis in structured care systems. From an industry side, companies like Boston Scientific and Medtronic continue growing advanced bronchoscopy systems that used in hospitals and specialist centers, following procedural innovation and accessibility. These outlines help support practical adoption and clinical training across North America.
France Bronchoscopy Market- Country Insights
France exhibits an increasingly developing environment for bronchoscopy implementation, reinforced by its public healthcare system and strong focus on respiratory disease administration. Government health data designates sustained clinical use of advanced diagnostic procedures, as the French Ministry of Health and Prevention (Ministere de la Sante et de la Prevention) promotes early detection of lung diseases through hospital-based respiratory care programs. The French National Institute of Health and Medical Research (INSERM) actively supports research on chronic respiratory conditions and minimally invasive pulmonary procedures, encouraging innovation in diagnostic tools such as bronchoscopy. In addition, national hospital data referenced by the Assurance Maladie highlights consistent use of pulmonary diagnostic procedures within public healthcare facilities. These proposals imitate a healthcare approach that arranges early diagnosis and less invasive treatment ways.
Followed by the development of respiratory diagnostics and rising inclination for minimally invasive lung inspection approaches, the bronchoscopy space contains a mix of medical technology firms and device manufacturers working together with regional suppliers. These participants offer flexible and rigid bronchoscopes, imaging systems, and supporting accessories through hospitals, procurement networks, direct institutional sales, and distribution partners. Companies such as Fujifilm Healthcare, Karl Storz, Ambu, Boston Scientific, and Pentax Medical (HOYA) focus on improving visualization quality, device maneuverability, and patient comfort while also strengthening service availability and training support for healthcare professionals. In recent progresses, Fujifilm Healthcare introduced an advanced ultrasonic bronchoscopy system designed to support more precise lung lesion assessment, while Ambu expanded its single-use bronchoscope portfolio to reduce infection risks in critical care settings.
In November 2025, Olympus announced a collaboration with the COPD Foundation aimed at improving patient education and awareness about severe emphysema and respiratory treatment options. The initiative enhances awareness, supports respiratory research, and strengthens minimally invasive treatment approaches for severe emphysema patients.
In March 2025, Johnson & Johnson MedTech (Auris Health - MONARCH platform) received regulatory clearance for MONARCH QUEST, an upgraded robotic-assisted bronchoscopy system designed to improve navigation accuracy and lung nodule access for minimally invasive pulmonary procedures. These advancement highlights improved precision, safer navigation, and expanded minimally invasive lung diagnosis through robotic-assisted bronchoscopy innovation.